Sana lays off staff as cell ther­a­py biotech awaits first clin­i­cal da­ta

Cell ther­a­py mak­er Sana Biotech­nol­o­gy is lay­ing off staff, based on about half a dozen em­ploy­ee posts on LinkedIn in re­cent days.

Sana ex­pects its first clin­i­cal da­ta lat­er this year — a key test of whether its so-called hy­poim­mune tech­nol­o­gy works at pre­vent­ing the re­jec­tion of al­lo­gene­ic cells, or those not orig­i­nat­ing from the pa­tient. Au­tol­o­gous, or self-de­rived, cell ther­a­pies have been on the mar­ket for about five years, but the al­lo­gene­ic ap­proach has lin­gered be­hind due to var­i­ous im­mune sys­tem com­plex­i­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER